Navigation Links
Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008
Date:3/5/2009

2008, our management and Board of Directors determined to explore and pursue various restructuring and cost reduction initiatives in order to conserve our liquidity, as well as various financial and strategic transactions that could potentially reduce or eliminate our existing debt obligations and improve our working capital position.

On July 7, 2008, we announced that our Board of Directors had authorized a transaction to create a new subsidiary, Angiotech Pharmaceutical Interventions Inc. ("API"), and that we would contribute certain business assets and intellectual property to API, primarily consisting of business assets of Angiotech other than the intellectual property and royalty revenue related to TAXUS(R) coronary stent systems. In connection with this transaction, we were to receive $200 to $300 million of new financing from new investors to establish API, which financing was targeted to reduce substantial amounts of our existing debt obligations with equivalent amounts of convertible debt bearing interest in additional equity of the newly created subsidiary in kind, as opposed to cash. This transaction, if approved by our shareholders and completed, would have substantially reduced our annual cash pay interest obligations.

On September 22, 2008, we announced that we had postponed the planned shareholder vote regarding the proposed API transaction. As of that date, given the time required for more extended discussions to address concerns of certain of our shareholders and bondholders, and given various other factors impacting our business and cash position (including lower expected revenues derived from BSC), we did not believe we would be able to satisfy the transaction condition with respect to the minimum level of cash and cash equivalents required to be held at the time of the transaction's close.

On September 22, 2008, we also announced that we would pursue various initiatives to reduce operating costs and further focus our busin
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related biology technology :

1. Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities
2. Angiotech Pharmaceuticals announces time change of conference call and webcast
3. Angiotech announces termination of note purchase agreement with Ares Management and New Leaf Venture Partners
4. Angiotech Announces Webcast and Call-in Numbers for Annual and Special General Meeting of Shareholders
5. Angiotech Announces Extension of the Expiration Date of its Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014
6. Angiotech receives CE Mark approval of HemoStream(TM) Chronic Dialysis Catheter
7. Angiotech wins before the UK House of Lords
8. Angiotech to Establish Separate Operating and Royalty Businesses
9. Angiotech To Commence Cash Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014
10. Angiotech announces market launch of Quill(TM) SRS MONODERM(TM)
11. Angiotechs corporate partner, Cook Medical, announces positive interim results for its Zilver(R) PTX(TM) clinical study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... --  PureTech , a science and technology R&D company ... technologies in the healthcare sector, announced today the appointment ... of the Board of Directors of Sanofi, to its ... a pleasure to know Chris for many years and ... together more closely now," said Dr. Robert Langer ...
(Date:2/26/2015)... Feb. 26, 2015   Synageva BioPharma Corp. ... company developing therapeutic products for rare disorders, today ... 2015 goals, other key objectives, and financial guidance.  ... today at 4:30 p.m. EST to review the ... To participate in today,s call by telephone, please ...
(Date:2/26/2015)... 2015 On behalf of biotech client ... Wilentz, Goldman & Spitzer, P.A. (Wilentz) secured ... against Genewiz Inc. in excess of $10 million. The ... trade secrets, and that it improperly hired one or ... order denying motions for judgment notwithstanding the verdict, a ...
(Date:2/26/2015)... (PRWEB) February 26, 2015 Already well ... gauging line by expanding its Length Gauge offerings with ... gauges. , Specifically, HEIDENHAIN’s pencil probe-style SPECTO ... force specification. Two new 1Vpp, 12mm stroke length ... force applications. One is a variant with a weak ...
Breaking Biology Technology:Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 3Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 4Synageva BioPharma Reports 2014 Full Year Financial Results 2Synageva BioPharma Reports 2014 Full Year Financial Results 3Synageva BioPharma Reports 2014 Full Year Financial Results 4Synageva BioPharma Reports 2014 Full Year Financial Results 5Synageva BioPharma Reports 2014 Full Year Financial Results 6Synageva BioPharma Reports 2014 Full Year Financial Results 7Synageva BioPharma Reports 2014 Full Year Financial Results 8Synageva BioPharma Reports 2014 Full Year Financial Results 9Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3Accuracy and Versatile Gauging Go Hand in Hand at HEIDENHAIN 2
... 4, 2012 Luminex Corporation (NASDAQ: LMNX) today announced ... Morgan Healthcare Conference to be held January 9 -12, ... http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) The investor presentation by Patrick ... at 1:30 p.m. Pacific time (4:30 p.m. Eastern time) on ...
... Jan. 4, 2012  Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today ... will be presenting at JP Morgan,s 30th Annual Healthcare ... Mr. Bentsur,s presentation is scheduled to take place on ... ET).  A live audio webcast of Mr. ...
... InterMune, Inc. (NASDAQ: ITMN) today announced that it ... sales of Esbriet® (pirfenidone) in Germany, as well as ... the open of the U.S. markets on Thursday, January ... be hosted by InterMune at 8:30 a.m. Eastern time ...
Cached Biology Technology:Luminex Corporation to Present at JP Morgan Healthcare Conference 2Keryx Biopharmaceuticals to Present at JP Morgan's 30th Annual Healthcare Conference 2InterMune to Report Unaudited Fourth Quarter Esbriet® Revenue and Business Update on January 5 2
(Date:2/18/2015)... -- Cepheid (NASDAQ: CPHD ) today announced that its ... investors to participate via webcast. , Cowen and Company ... March 3, 2015 at 11.20 a.m. Eastern Time , ... Wednesday, March 4, 2015 at 10.25 a.m. Eastern Time ... for these events, please visit Cepheid,s website at http://ir.cepheid.com ...
(Date:2/12/2015)... , Feb. 12, 2015 NXT-ID, Inc. ... the "Company"), a biometric authentication company focused on the ... filed provisional patent 62/113114 for DISTRIBUTED METHOD ... The patent further establishes NXT-ID,s position in ... intellectual property portfolio the ability for multiple devices to ...
(Date:2/9/2015)... RICHARDSON, Texas , Feb. 9, 2015  Lintec ... novel fabrication methods for carbon nanotube (CNT) macrostructures, including ... Texas at Dallas (UTD). Leveraging the vast ... Tokyo, Japan , Lintec of America ... Richardson, TX , focusing on scaling ...
Breaking Biology News(10 mins):Cepheid to Webcast Upcoming Financial Presentations 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4
... experts on biodiversity will gather from the 21th to the ... the transfer of biodiversity knowledge from the scientific community into ... in a project funded by the European Commission: " BiodiversityKnowledge ... practitioners to help all actors in the field of biodiversity ...
... Exercise clears the mind. It gets the blood pumping ... is familiar territory, but Dartmouth,s David Bucci thinks there ... several years there have been data suggesting that neurobiological ... work here," says Bucci, an associate professor in the ...
... Scientists at Queen Mary, University of London have ... underlying causes of psychiatric disorders. The study, published ... found zebrafish can modify their behaviour in response to ... School of Biological and Chemical Sciences who led the ...
Cached Biology News:A network of knowledge on biodiversity and ecosystem services in Europe 2Dartmouth researchers are learning how exercise affects the brain 2Dartmouth researchers are learning how exercise affects the brain 3Zebrafish could hold the key to understanding psychiatric disorders 2
... polystyrene with frosted labeling surfaces, volume ... counting. 100% integrity tested. Linkage: This ... number, created to easily match Cornings ... yet, please order under the old ...
Automated Cell Culture Flask...
... system, 100-240 V, uses multiplex suspension array ... of up to 100 proteins and peptides ... array is composed of up to 100 ... be conjugated with a unique reactant specific ...
...
Biology Products: